Faeth Therapeutics Announces Investor Engagement and Analyst Support
Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical‑stage oncology company focused on multi‑node inhibition therapies, has outlined a series of upcoming investor engagement events and confirmed continued analyst support for its stock.
Investor Conference Participation
On 11 November 2026, Faeth’s management announced participation in the following investor conferences:
- Guggenheim 3rd Annual Healthcare Innovation Conference – Wednesday, 11 November 2026 in Boston, MA.
- Jefferies Global Healthcare Conference – Tuesday, 17 November 2026 in London, UK.
- Presentation scheduled for 8:30 AM GMT.
Live webcasts and subsequent replays (available for approximately 90 days) will be hosted on the company’s investor relations site at investors.faeththerapeutics.com.
Focus of the Company
Faeth’s pipeline centers on its lead program PIKTOR, an all‑oral combination of serabelisib and sapanisertib. The investigational therapy is under development for endometrial and breast cancer and aims to achieve multi‑node inhibition of critical oncogenic pathways. The company was co‑founded in 2019 by Anand Parikh and Oliver Maddocks, Ph.D., alongside prominent scientific founders, including the discoverer of the PI3K pathway, Lewis Cantley, Ph.D.
Analyst Ratings
Recent analyst actions demonstrate sustained confidence in Faeth’s prospects:
| Date | Analyst | Rating | Source |
|---|---|---|---|
| 10 Nov 2026 | Baird | Buy (reaffirmed) | de.investing.com |
| 10 Nov 2026 | H.C. Wainwright | Buy (reiterated) | www.investing.com |
| 09 Nov 2026 | TD Cowen | Buy (maintained) | www.investing.com |
Additionally, H.C. Wainwright and TD Cowen have issued purchase recommendations based on recent PIK‑201 data and trial results.
Recent Data Highlights
Faeth’s Phase II data for PIKTOR have attracted attention from the oncology community. The combination therapy’s performance in early‑stage trials has been noted as a potential advancement for cancer treatments targeted by antibody‑drug conjugate (ADC) leaders.
Market Context
As of 9 November 2026, Faeth’s closing price stood at $12.92. The stock’s 52‑week high was $42.14 (7 September 2026), while the 52‑week low was $7.45 (4 December 2025). The company’s market capitalization is approximately $321 million USD, and its price‑to‑earnings ratio is -0.51, reflecting its clinical‑stage status.
Faeth Therapeutics continues to pursue multi‑node therapeutic strategies while engaging investors and maintaining analyst support, positioning itself as a notable player in the oncology biotechnology landscape.
